Literature DB >> 22484618

Differentiation and enrichment of cardiomyocytes from human pluripotent stem cells.

Chunhui Xu1.   

Abstract

Human cardiomyocytes derived from pluripotent stem cells hold great promise for cardiac cell therapy, disease modeling, drug discovery, and the study of developmental biology. Reaching these potentials fully requires the development of methods that enable efficient and robust generation of cardiomyocytes with expected characteristics. This review summarizes and discusses up-to-date methods that have been used to derive and enrich human cardiomyocytes from pluripotent stem cells, provides a brief overview of in vitro and in vivo characterization of these cardiomyocytes, and considers future advancement needed to further harness the power of these cells.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22484618     DOI: 10.1016/j.yjmcc.2012.03.012

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  18 in total

1.  Efficient differentiation of cardiomyocytes from human pluripotent stem cells with growth factors.

Authors:  Rajneesh Jha; Ren-He Xu; Chunhui Xu
Journal:  Methods Mol Biol       Date:  2015

2.  Improved targeting and enhanced retention of the human, autologous, fibroblast-derived, induced, pluripotent stem cells to the sarcomeres of the infarcted myocardium with the aid of the bioengineered, heterospecific, tetravalent antibodies.

Authors:  Marek Malecki
Journal:  J Stem Cell Res Ther       Date:  2013-05-06

Review 3.  Dendritic cells derived from pluripotent stem cells: Potential of large scale production.

Authors:  Yan Li; Meimei Liu; Shang-Tian Yang
Journal:  World J Stem Cells       Date:  2014-01-26       Impact factor: 5.326

4.  Pluripotent stem cells as a platform for cardiac arrhythmia drug screening.

Authors:  Jordan S Leyton-Mange; David J Milan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-09

5.  Myosin light chain 2-based selection of human iPSC-derived early ventricular cardiac myocytes.

Authors:  Alexandra Bizy; Guadalupe Guerrero-Serna; Bin Hu; Daniela Ponce-Balbuena; B Cicero Willis; Manuel Zarzoso; Rafael J Ramirez; Michelle F Sener; Lakshmi V Mundada; Matthew Klos; Eric J Devaney; Karen L Vikstrom; Todd J Herron; José Jalife
Journal:  Stem Cell Res       Date:  2013-09-18       Impact factor: 2.020

Review 6.  Marching towards regenerative cardiac therapy with human pluripotent stem cells.

Authors:  Kevin O Maher; Chunhui Xu
Journal:  Discov Med       Date:  2013-06       Impact factor: 2.970

Review 7.  Implementing genome-driven personalized cardiology in clinical practice.

Authors:  Ares Pasipoularides
Journal:  J Mol Cell Cardiol       Date:  2018-01-16       Impact factor: 5.000

Review 8.  Human iPSC-derived cardiomyocytes and tissue engineering strategies for disease modeling and drug screening.

Authors:  Alec S T Smith; Jesse Macadangdang; Winnie Leung; Michael A Laflamme; Deok-Ho Kim
Journal:  Biotechnol Adv       Date:  2016-12-20       Impact factor: 14.227

Review 9.  Preconditioning stem cells for in vivo delivery.

Authors:  Sébastien Sart; Teng Ma; Yan Li
Journal:  Biores Open Access       Date:  2014-08-01

10.  Cardiac Toxicity From Ethanol Exposure in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Authors:  Antonio Rampoldi; Monalisa Singh; Qingling Wu; Meixue Duan; Rajneesh Jha; Joshua T Maxwell; Joshua M Bradner; Xiaoyu Zhang; Anita Saraf; Gary W Miller; Greg Gibson; Lou Ann Brown; Chunhui Xu
Journal:  Toxicol Sci       Date:  2019-05-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.